Unlike other pro‐inflammatory TNF family cytokines, TRAIL has shown beneficial immunomodulatory effects in T1D: blocking or genetically deleting TRAIL in NOD mouse models accelerates and exacerbates diabetes, whereas administering exogenous TRAIL or increasing TRAIL expression mitigates disease development [61, 62]. This evidence concerns the gene TNFSF10 and type 1 diabetes mellitus.